OrthoLogic Chrysalin Phase III Fracture Repair NDA Study To Begin This Fall
This article was originally published in The Gray Sheet
Executive Summary
OrthoLogic believes that pursuing approval of its orthobiologic product Chrysalin through a new drug application (NDA) will enable fuller discussion of the product's method of action in marketing materials
You may also be interested in...
OrthoLogic, dj Orthopedics Seek Alternative Paths To Healing Bones
OrthoLogic will focus on commercializing its Chrysalin synthetic peptide technology for tissue and bone repair with proceeds from the sale of its electromagnetic bone stimulation business
OrthoLogic, dj Orthopedics Seek Alternative Paths To Healing Bones
OrthoLogic will focus on commercializing its Chrysalin synthetic peptide technology for tissue and bone repair with proceeds from the sale of its electromagnetic bone stimulation business
Synthes Chooses Alternative-To-BMP Route In Bone Growth Factor Search
Synthes-Stratec plans to forego immediate development of an orthobiologic bone growth factor, citing doubts about the product's feasibility in musculoskeletal repair applications